3 Superb High-Yield Dividend Stocks With Yields North of 5% That Make for No-Brainer Buys Right Now

Three high-yield income names are highlighted: Realty Income (O) yields ~5.8% and reported Q3 2025 AFFO/sh of $1.08 and revenue of $1.47B (+11% YoY) with 98.7% occupancy and a 15,500+ property portfolio; Pfizer (PFE) yields ~6.8%, generated $14B free cash flow in the last 12 months and reported 2024 revenues of $63.6B (+7% operational, +12% ex-COVID) while pursuing large acquisitions (Seagen $43B, Metsera) and an oncology/obesity pipeline; Verizon (VZ) yields just under 7%, posted Q3 2025 revenue of $33.8B (+1.5% YoY), consolidated net income of $5.1B, nine‑month FCF of $15.8B, and is executing a cost-cutting/turnaround including ~13,000 layoffs and debt reduction. Each company’s long dividend history and current yields are framed as attractive for long-term income investors, though risks include patent cliffs (Pfizer), business restructuring and subscriber pressures (Verizon), and sector-specific risks for real estate (Realty Income).

Analysis

Market structure: Net-lease REITs (O) and grocery/convenience-anchored landlords are the immediate winners — high occupancy (98.7%) and predictable NNN rent recapture (103.5%) preserve AFFO and make O less rate-sensitive than mall landlords. Large-cap pharma (PFE) with $14B FCF and the Seagen/Metsera assets benefit from scale and diversified revenue as COVID sales fade; telcos (VZ) face pricing pressure but generate strong FCF to fund dividends while executing a multi-quarter turnaround. Cross-asset: higher equity yields compress relative to core IG bonds (watch 10y moves ±50bp); REIT and telco equity vols will rise with any rate shock, lifting options premia and CDS spreads on high-debt telcos.

Risk assessment: Key tail risks — a +100bp rapid move in Treasury yields could knock REIT NAVs ~8–12% in 3–6 months and force dividend trimming if leverage re-prices; failed late-stage oncology or GLP-1 trials for Metsera could remove Pfizer upside and pressure its multiple quickly. Time buckets: immediate (days) — quarterly reports and short-term volatility; short-term (weeks–months) — FDA readouts, enrollment/earnings cadence; long-term (12–36 months) — Pfizer oncology commercialization and Verizon restructuring cadence. Hidden dependencies include tenant concentration shifts in O’s Europe exposure and Verizon’s reliance on prepaid growth to offset postpaid churn.

Trade implications: Direct plays — establish a measured 2–3% long in O to capture ~5.8% yield with covered-call overlays 5–8% OTM for 1–3 month tenors; size 1–2% long in PFE via 9–15 month call spreads (buy 25–30% OTM, sell 50% OTM) to lever potential oncology/obesity wins while limiting premium. For VZ, use a tactical 1–2% long funded by selling cheap OTM credit spreads if restructuring updates show sequential improvement in net adds; protect with 3–6 month puts if unsecured debt/EBITDA >4.5x or postpaid losses persist two quarters.

Contrarian angles: The market understates Pfizer’s procedural optionality — $14B FCF + inorganic pipeline gives dividend safety, so PFE may be oversold by ~15–20% vs fundamentals if key approvals land. Realty Income’s monthly dividend and net-lease model are underappreciated if rates stabilize; a 50–75bp Fed pivot in 6–12 months would likely re-rate O by +10–15%. Conversely, consensus underestimates execution risk at Verizon — restructurings historically take 12–24 months and could keep valuation depressed even if cash flow recovers.

Key Decisions for Investors

• Establish a 2–3% tactical long position in Realty Income (O) over 2–4 weeks to average in; simultaneously sell 1–3 month covered calls 5–8% OTM to boost yield. Hard stop: liquidate if AFFO per share misses consensus by >4% or portfolio occupancy falls below 97% within two quarters.
• Allocate 1–2% to a directional Pfizer (PFE) options structure: buy 9–15 month call spread (buy 25–30% OTM, sell ~50% OTM) to capture upside from Seagen/Metsera catalysts while capping premium. Take-profit: +80% on spread; stop-loss: reduce/exit on any negative pivotal FDA decision or if trailing-12m FCF declines >20% y/y.
• Initiate a cautious 1–2% position in Verizon (VZ) only after a >3% price pullback that pushes yield above ~6.8%; hedge with 3–6 month 3–5% OTM protective puts or buy a put spread sized at 50% of the equity position. Exit/trim if postpaid phone net losses continue for two consecutive quarters or unsecured debt/EBITDA breaches 4.5x.
• Short-duration tactical pair: long O (target 2%) vs. short a mall-focused REIT or REIT ETF (target 2%) for 3–9 months to exploit net-lease vs. mall divergence; unwind if 10y Treasury falls >50bp (re-rating risk) or if O’s spread to VNQ compresses <100bp.